Severe pneumonia mortality in elderly patients is associated with downregulation of toll-like receptors 2 and 4 on monocytes

American Journal of the Medical Sciences

Volumn 347, Issue 1, 2014, Pages 34-41

  Tang, Lunxian ^a   Li, Qinchuan ^a   Bai, Jianwen ^a   Zhang, Hua ^b   Lu, Ying ^a,c   Ma, Shaolin ^a  

^a TONGJI UNIVERSITY   (China)

^b Geriatric Department   (United States)

^c Central Laboratory Department   (United States)

Author keywords

Elderly patients; Mortality; Severe pneumonia; TLR2; TLR4

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACINETOBACTER BAUMANNII; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROBACTERIACEAE; ENTEROCOCCUS; FEMALE; FUNGUS; HUMAN; HUMAN CELL; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOCYTE; MORTALITY; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; RECEPTOR DOWN REGULATION; SCORING SYSTEM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APACHE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MONOCYTES; PNEUMONIA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891829733     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182798583     Document Type: Article

References (31)

1. Sharma S, Maycher B, Eschun G. Radiological imaging in pneumonia: recent innovations. Curr Opin Pulm Med 2007;13:159-69.
2. Chong CP, Street PR. Pneumonia in the elderly: a review of severity assessment, prognosis, mortality, prevention, and treatment. South Med J 2008;101:1134-40; quiz 1132, 1179.
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365: 217-23.
4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(suppl 2):S27-72.
5. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008;7:467-79.
6. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008;205:323-9.
7. Kelly E, MacRedmond RE, Cullen G, et al. Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia? Respirology 2009;14:210-6.
8. Hedayat M, Netea MG, Rezaei N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 2011;11:702-12.
9. Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia. Criteria for evaluating diagnostic techniques. Chest 1992;102:553S-6S.
10. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2009;103:309-16.
11. van Duin D, Shaw AC. Toll-like receptors in older adults. J Am Geriatr Soc 2007;55:1438-44.
12. Hinojosa E, Boyd AR, Orihuela CJ. Age-associated inflammation and toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia. J Infect Dis 2009;200:546-54.
13. Schaaf B, Luitjens K, Goldmann T, et al. Mortality in human sepsis is associated with downregulation of Toll-like receptor 2 and CD14 expression on blood monocytes. Diagn Pathol 2009;4:12.
14. Nyugen J, Agrawal S, Gollapudi S, et al. Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol 2010;30:806-13.
15. Wieland CW, van Lieshout MH, Hoogendijk AJ, et al. Host defence during Klebsiella pneumonia relies on haematopoietic-expressed Tolllike receptors 4 and 2. Eur Respir J 2011;37:848-57.
16. Weighardt H, Holzmann B. Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 2007;212:715-22.
17. Gao H, Leaver SK, Burke-Gaffney A, et al. Severe sepsis and Tolllike receptors. Semin Immunopathol 2008;30:29-40.
18. Tsujimoto H, Ono S, Efron PA, et al. Role of Toll-like receptors in the development of sepsis. Shock 2008;29:315-21.
19. Ramphal R, Balloy V, Jyot J, et al. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol 2008;181:586-92.
20. Puliti M, Uematsu S, Akira S, et al. Toll-like receptor 2 deficiency is associated with enhanced severity of group B streptococcal disease. Infect Immun 2009;77:1524-31.
21. Dunston CR, Griffiths HR. The effect of ageing on macrophage Tolllike receptor-mediated responses in the fight against pathogens. Clin Exp Immunol 2010;161:407-16.
22. Dessing MC, Schouten M, Draing C, et al. Role played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung inflammation and coagulation. J Infect Dis 2008;197:245-52.
23. Daubeuf B, Mathison J, Spiller S, et al. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 2007;179:6107-14.
24. Ianaro A, Tersigni M, D'Acquisto F. New insight in LPS antagonist. Mini Rev Med Chem 2009;9:306-17.
25. Roger T, Froidevaux C, Le Roy D, et al. Protection from lethal gramnegative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 2009;106:2348-52.
26. Yandiola PP, Capelastegui A, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009;135:1572-9.
27. Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011; 37:214-23.
28. Ma HM, Tang WH, Woo J. Predictors of in-hospital mortality of older patients admitted for community-acquired pneumonia. Age Ageing 2011; 40:736-41.
29. Tseng JS, Chan MC, Hsu JY, et al. Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia. Respirology 2008;13:505-9.
30. Bloos F, Marshall JC, Dellinger RP, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011;15:R88.
31. Park JH, Wee JH, Choi SP, et al. The value of procalcitonin level in community-acquired pneumonia in the ED. Am J Emerg Med 2012;30: 1248-54.